NCT02789345 2024-02-05A Study of Ramucirumab (LY3009806) or Necitumumab (LY3012211) Plus Osimertinib in Participants With Lung CancerEli Lilly and CompanyPhase 1 Completed29 enrolled 16 charts
NCT02392507 2020-11-19A Study of Nab-Paclitaxel and Carboplatin Plus Necitumumab (LY3012211) in Participants With Stage IV Squamous NSCLCEli Lilly and CompanyPhase 2 Completed54 enrolled 16 charts
NCT01763788 2019-10-25A Study of Necitumumab in the First-Line Treatment of Stage IV Squamous Non-Small Cell Lung Cancer (NSCLC)Eli Lilly and CompanyPhase 1/2 Completed192 enrolled 24 charts
NCT01606748 2019-09-30A Drug-Interaction Study of Necitumumab (IMC-11F8) in Combination With Gemcitabine-CisplatinEli Lilly and CompanyPhase 2 Completed35 enrolled 23 charts
NCT01769391 2019-09-20A Study of Necitumumab and Chemotherapy in Participants With Stage IV Squamous Non-Small Cell Lung CancerEli Lilly and CompanyPhase 2 Completed167 enrolled 17 charts
NCT01788566 2016-06-27A Study of Gemcitabine-Cisplatin Chemotherapy Plus Necitumumab in the First-Line Treatment of Participants With Squamous Lung CancerEli Lilly and CompanyPhase 2 Completed61 enrolled 14 charts